Kindred Biosciences Notes Positive Results of Potential CPV Treatment in Dogs
Kindred Biosciences, a biopharmaceutical company focused on saving and improving the lives of pets, today announced positive results from a pivotal efficacy study concerning the prevention and potential treatment of canine parvovirus (CPV).
The study looked into KIND-030, a monoclonal antibody targeting CPV. KIND-030 binds to critical portions of the virus, preventing the virus from entering into cells. The results showed 100 percent efficacy in the prevention of parvovirus, as well as a mortality benefit in the treated group.
In this randomized, blinded, placebo-controlled study, KIND-030 was administered to dogs as prophylactic therapy to prevent clinical signs of CPV infection. The primary objectives of the study were met. All of the placebo-control dogs developed parvovirus infection as predefined in the study protocol, while none of the KIND-030 treated dogs developed the disease. Furthermore, the parvovirus challenge resulted in 60 percent mortality rate in the control dogs compared to 0 percent mortality rate in the KIND-030 treated dogs.
KIND-030 is currently being pursued for two indications in dogs: prophylactic therapy to prevent clinical signs of canine parvovirus infection and treatment of established parvovirus infection. The pivotal efficacy study for the treatment indication and pivotal safety studies remain on track to be completed by year-end 2020, with approval expected by early 2021.
“We are very pleased with these positive study results, which for the first time provide hope to dogs exposed to this deadly disease,” said KindredBio’s CEO Richard Chin. “Parvovirus represents a significant unmet medical need. We believe KIND-030 can transform the way parvovirus infections are treated and prevented.”
CPV is the most significant and contagious viral cause of enteritis in dogs, especially puppies, with mortality rates reportedly as high as 91 percent. There are currently no Food and Drug Administration or United States Department of Agriculture (USDA) approved treatments for CPV, nor any other available treatment. Currently, owners spend up to thousands of dollars per puppy in supportive care for CPV, with average cost of $1,200.